116 related articles for article (PubMed ID: 28880268)
21. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.
Mehraj U; Ganai RA; Macha MA; Hamid A; Zargar MA; Bhat AA; Nasser MW; Haris M; Batra SK; Alshehri B; Al-Baradie RS; Mir MA; Wani NA
Cell Oncol (Dordr); 2021 Dec; 44(6):1209-1229. PubMed ID: 34528143
[TBL] [Abstract][Full Text] [Related]
22. miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma.
Xue W; Wang Y; Xie Y; Yang C; Gong Z; Guan C; Wei C; Zhu C; Niu Z
Front Oncol; 2021; 11():634841. PubMed ID: 34262855
[TBL] [Abstract][Full Text] [Related]
23. Cancer Statistics, 2021.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2021 Jan; 71(1):7-33. PubMed ID: 33433946
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and prognostic value of MCM3 and its interacting proteins in hepatocellular carcinoma.
Li HT; Wei B; Li ZQ; Wang X; Jia WX; Xu YZ; Liu JY; Shao MN; Chen SX; Mo NF; Zhao D; Zuo WP; Qin J; Li P; Zhang QL; Yang XL
Oncol Lett; 2020 Dec; 20(6):308. PubMed ID: 33093917
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint signaling and cancer immunotherapy.
He X; Xu C
Cell Res; 2020 Aug; 30(8):660-669. PubMed ID: 32467592
[TBL] [Abstract][Full Text] [Related]
26. Hepatocellular Carcinoma-How to Determine Therapeutic Options.
Mehta N
Hepatol Commun; 2020 Mar; 4(3):342-354. PubMed ID: 32140653
[TBL] [Abstract][Full Text] [Related]
27. Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection.
Yu B; Liang H; Ye Q; Wang Y
J Gastrointest Surg; 2021 Jan; 25(1):112-124. PubMed ID: 32128678
[TBL] [Abstract][Full Text] [Related]
28. The emerging roles of KPNA2 in cancer.
Han Y; Wang X
Life Sci; 2020 Jan; 241():117140. PubMed ID: 31812670
[TBL] [Abstract][Full Text] [Related]
29. Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer.
Drucker E; Holzer K; Pusch S; Winkler J; Calvisi DF; Eiteneuer E; Herpel E; Goeppert B; Roessler S; Ori A; Schirmacher P; Breuhahn K; Singer S
Cell Commun Signal; 2019 Nov; 17(1):159. PubMed ID: 31783876
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
31. Wip1 cooperates with KPNA2 to modulate the cell proliferation and migration of colorectal cancer via a p53-dependent manner.
Wang P; Zhao Y; Liu K; Liu X; Liang J; Zhou H; Wang Z; Zhou Z; Xu N
J Cell Biochem; 2019 Sep; 120(9):15709-15718. PubMed ID: 31127650
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-139 inhibits hepatocellular carcinoma cell growth through down-regulating karyopherin alpha 2.
Zan Y; Wang B; Liang L; Deng Y; Tian T; Dai Z; Dong L
J Exp Clin Cancer Res; 2019 May; 38(1):182. PubMed ID: 31046781
[TBL] [Abstract][Full Text] [Related]
33. Upregulated KPNA2 promotes hepatocellular carcinoma progression and indicates prognostic significance across human cancer types.
Guo X; Wang Z; Zhang J; Xu Q; Hou G; Yang Y; Dong C; Liu G; Liang C; Liu L; Zhou W; Liu H
Acta Biochim Biophys Sin (Shanghai); 2019 Mar; 51(3):285-292. PubMed ID: 30883648
[TBL] [Abstract][Full Text] [Related]
34. Karyopherin subunit-α 2 expression accelerates cell cycle progression by upregulating CCNB2 and CDK1 in hepatocellular carcinoma.
Gao CL; Wang GW; Yang GQ; Yang H; Zhuang L
Oncol Lett; 2018 Mar; 15(3):2815-2820. PubMed ID: 29435009
[TBL] [Abstract][Full Text] [Related]
35. Prognostic implication of NQO1 overexpression in hepatocellular carcinoma.
Lin L; Sun J; Tan Y; Li Z; Kong F; Shen Y; Liu C; Chen L
Hum Pathol; 2017 Nov; 69():31-37. PubMed ID: 28964792
[TBL] [Abstract][Full Text] [Related]
36. Microvascular Invasion in Hepatocellular Carcinoma: Bridging the Global Gap between Imaging and Clinical Practice.
Ballard DH
Acad Radiol; 2023 Aug; 30(8):1528-1530. PubMed ID: 37316367
[No Abstract] [Full Text] [Related]
37. Interleukin-6: A New Marker of Advanced-Sarcopenic HCC Cirrhotic Patients.
Dalbeni A; Natola LA; Garbin M; Zoncapè M; Cattazzo F; Mantovani A; Vella A; Canè S; Kassem J; Bevilacqua M; Conci S; Campagnaro T; Ruzzenente A; Auriemma A; Drudi A; Zanoni G; Guglielmi A; Milella M; Sacerdoti D
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173873
[TBL] [Abstract][Full Text] [Related]
38. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Serum FGL1 as Diagnostic Markers for HBV-Related Hepatocellular Carcinoma.
Cai X; Tang D; Chen J; Li H; Zhang P
Lab Med; 2023 May; 54(3):270-281. PubMed ID: 36219698
[TBL] [Abstract][Full Text] [Related]
40. HIF-1α-activated long non-coding RNA KDM4A-AS1 promotes hepatocellular carcinoma progression via the miR-411-5p/KPNA2/AKT pathway.
Chen T; Liu R; Niu Y; Mo H; Wang H; Lu Y; Wang L; Sun L; Wang Y; Tu K; Liu Q
Cell Death Dis; 2021 Dec; 12(12):1152. PubMed ID: 34903711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
